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Influence of untranslated regions on retroviral
mRNA transfer and expression
Anne Prel1,4, Luc Sensébé2,3 and Jean-Christophe Pagès1*
Abstract
Background: Deliberate cellular reprogramming is becoming a realistic objective in the clinic. While the origin of
the target cells is critical, delivery of bioactive molecules to trigger a shift in cell-fate remains the major hurdle. To
date, several strategies based either on non-integrative vectors, protein transfer or mRNA delivery have been
investigated. In a recent study, a unique modification in the retroviral genome was shown to enable RNA transfer
and its expression.
Results: Here, we used the retroviral mRNA delivery approach to study the impact of modifying gene-flanking
sequences on RNA transfer. We designed modified mRNAs for retroviral packaging and used the quantitative
luciferase assay to compare mRNA expression following viral transduction of cells. Cloning the untranslated regions
of the vimentin or non-muscular myosin heavy chain within transcripts improved expression and stability of the
reporter gene while slightly modifying reporter-RNA retroviral delivery. We also observed that while the modified
retroviral platform was the most effective for retroviral mRNA packaging, the highest expression in target cells was
achieved by the addition of a non-viral UTR to mRNAs containing the packaging signal.
Conclusions: Through molecular engineering we have assayed a series of constructs to improve retroviral mRNA
transfer. We showed that an authentic RNA retroviral genomic platform was most efficiently transferred but that
adding UTR sequences from highly expressed genes could improve expression upon transfection while having only
a slight effect on expression from transferred RNA. Together, these data should contribute to the optimisation of
retroviral mRNA-delivery systems that test combinations of UTRs and packaging platforms.
Keywords: RNA, UTR, Retroviral transfer, Retroviral vectors, Transient expression
Background
The transfer of non-integrative, non-DNA genetic infor-
mation to trigger changes in cell-fate is a challenge in
advanced therapeutics [1]. Achieving efficient transfer of
active factors is crucial for controlling cell differentiation
programs in various cell types including induced pluripo-
tent stem cells (iPS) [2]. A viral approach could offer several
advantages compared to potentially toxic chemical
approaches, particularly for in vivo applications that might
require repeated administration.
As mRNA could be a useful molecule to trigger cellular
differentiation [2], access to a large amount of transferred
mRNA is required. However, the efficiency of expression
of transferred RNA may also profoundly influence the
extent of the expected phenotypic changes. Under physio-
logical conditions, cellular RNA expression is controlled
by sequences flanking the translated region, the so-called
5 and 3 untranslated regions (UTRs) [3,4]. Investigation
of the regulation of RNA translation has demonstrated
that RNA biological availability generally depends on
binding of cellular proteins and regulatory RNAs to UTRs
[5]. Therefore, we anticipated that UTR sequences could
have a direct impact on transgene expression for RNAs
transferred using viral vectors. In conventional expression
systems, such as commercially available ones, UTRs are not
generally considered for modification. Most expression vec-
tors rely on a favourable Kozak sequence, a heterologous
intron and a ubiquitous, efficient polyadenylation signal,
which makes these vectors amenable to improvement. For
retroviral vectors, the addition of transcriptional regulatory
elements, wPRE for example, improves polyadenylation and
increases vector titers [6].
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The RNA content of retroviral particles can be quite
diverse. It includes specifically recruited RNAs bearing the
packaging signal (psi) and a wide variety of captured, small
cytoplasmic RNAs [7-10]. Any mRNA can be packaged
into retroviral particles provided that a canonical psi
sequence is cloned into the transcript [11-13]. More
recently, solely inactivating the primer binding site has been
sufficient to convert integrative retroviral vectors into RNA
delivery systems [14]. For retroviruses, it was shown that
incoming genomes are directed to cellular compartments
poorly accessible to RNA interference [15], accordingly they
could also be poorly translated. In infected cells, wild-type
retrovirus genome translation is mostly supported by
capped mRNAs produced upon integration. Interestingly,
the presence of an internal ribosomal entry site within the
retroviral genome suggests that some direct translation of
the genomic RNA is achievable [16]. However, the level of
this putative retroviral expression from incoming recom-
binant retroviral RNAs is not known. To date, no studies
have addressed this question in the context of vectors.
In the present study, we aimed to engineer retrovirally
packaged mRNAs. For this, we designed constructs to
improve both the retroviral delivery of RNAs and their effi-
cient expression after transfer into target cells. RNA biology
has recently been renewed by the study of regulating RNAs,
including miRNAs [17]. The half-life of cellular RNA
depends on RNA processing by the RNA-induced silencing
complex, as well as the complex process of mRNA decay.
Influencing the mRNA decay machinery at the cellular level
to improve the availability of RNAs in relevant cells is
hardly conceivable. Moreover, drug-induced neutralisation
of mRNA decay, which would favour the expression of a
transferred RNA, could induce profound and detrimental
dysregulation of the target cell differentiation program.
Therefore, we evaluated and modulated mRNA stability by
modifying the 5 and 3 UTR characteristics of mRNA.
Because these modified RNAs were also designed to permit
retroviral mobilisation, we used psi-containing RNAs.
Results
Engineering mRNA
MLV-based retroviral particles were used as vehicles to
recruit and transfer mRNAs of interest [12]. Galla and
collaborators have shown that such transfer was possible
by modifying a retroviral vector, provided that the vector
RNA has been disabled for reverse transcription while
maintaining the packaging signal [14,18]. In these pioneer
studies, the use of a Cre-based recombination system
increased signal detection in retroviral-transduced cells.
Because RNA stability and subsequent protein production
of many mRNAs is dictated by elements in their UTRs, we
designed a series of constructs with various 5 and 3
UTRs flanking a luciferase gene as a marker [4]. Luciferase
has suitable sensitivity and a short half-life for easily
detecting the effect of an improvement introduced with
the transferred mRNA [19,20].
We selected 5 and 3 UTRs from genes known to have a
high level of expression such as vimentin and non-
muscular myosin heavy chain (NMHC) [21,22]. β-globin or
β-actin were also tested but were eliminated early in the
evaluation process (data not shown). Vimentin is a protein
which assembles into type III intermediate filaments and a
marker of cells of mesenchymal origin (e.g., fibroblasts and
myofibroblasts). Vimentin is one of the most widely
expressed and highly conserved proteins of the type III IF
protein family [21]. The MYH9 gene encodes a large (224
kDa) cytoplasmic myosin IIA heavy chain that contains an
IQ domain (Isoleucine-Glutamine domain) and a myosin
head-like domain and is involved in several important func-
tions including cytokinesis, cell motility and maintenance
of cell shape [23]. To enable the recruitment of these
UTR-containing mRNAs into retroviral particles, we
inserted a minimal sequence covering the packaging
signal of MLV (+206 to +512, Genbank: AF033811) at
the 3 end of the reporter gene, 5 to the tested 3 UTR
(Figure 1) [8,11,24]. Hereafter, all constructs containing the
5, 3 UTRs and the minimal psi flanking the luciferase
gene were called pcDNA-Luc-UTR-psi or simple mRNAs.
In parallel, to promote efficient mRNA recruitment into
retroviral particles, we used mRNAs from a regular retro-
viral vector (pBullet-Luc) that we truncated at its 3 end to
prevent reverse transcription and genomic integration [25].
We substituted the ppt and the 3 LTR of pBullet-Luc with
the 3 UTR of vimentin or NMHC, followed by the polyA
signal from the bovine growth hormone (pCMV-5LTR-
psi-Luc and pCMV-5LTR-psi-Luc-3UTR, see Methods).
Hence, all the pBullet based constructs had the same
retroviral-derived 5 and differed one to the other only by
the 3 UTR region, and these vectors were referred as
truncated retroviral mRNAs. The mRNA transcribed
from these vectors contained optimal MLV packaging
sequence (+206; +1106, Genbank: AF033811) [8,11].
We next studied retroviral packaging, using a transient
MLV retroviral complementation system. The pMN
complementation vector, encoding intact GAG and POL
genes, was transfected together with a plasmid express-
ing an envelope allowing for a wide choice of target cells
(Figure 1). Usually, the pantropic VSV-G envelope is
used for this purpose. However, spontaneous, unspecific
budding of cellular vesicles, leading to pseudoparticle
formation has been described when using the VSV-G
envelope [26,27]. Importantly, these VSV-G-vesicles
were shown to contain various cellular components,
including non-specifically mobilised cellular RNAs [28],
a condition potentially leading to flawed interpretation
of mobilisation data. Thus, we chose to pseudotype the
particles by using the 4070A amphotropic envelope,
targeting most cells of human origin (Figure 1).
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Evaluating mRNA content in transfected cells
To evaluate the effect of the UTR from vimentin or NMHC
on luciferase expression, 293FT cells were transfected with
the different constructs (pcDNA-Luc-psi or pcDNA-
Luc-UTR-psi and pCMV-5LTR-psi-Luc+/−3UTR). All
constructs allowed luciferase expression (See below).
We first studied the duration of mRNA cytoplasmic
availability following transcription, with the UTR-minus
pcDNA-Luc-psi as a control. Quantitative RT-PCR
(RT-qPCR) revealed that vimentin UTR did not impact
on mRNA expression, whereas NMHC seemed to reduce
it (Figure 2A; D + 1). To monitor the persistence of the
RNA following transcription, cells were treated with the
transcription inhibitor actinomycin D [29], at day one
following transfection. The luciferase mRNA level was
then measured 2 to 4 days after transfection, reflecting the
half-life of the mRNA (Figure 2A). As compared with
pcDNA-Luc-psi alone, pcDNA-Luc-Vimentin-psi produced
the next-highest mRNA level, while NMHC UTRs were
not efficient at stabilizing the mRNA level (Figure 2A). To
further understand the effect of actinomycin D, we calcu-
lated the relative amount of each individual construct
following transcription inhibition. Under these conditions,
actinomycin D induced a decrease of all mRNA
levels in transfected cells (Figure 2B). Unexpectedly,
as compared with pcDNA-Luc-Vimentin-psi or pcDNA-
Luc-NMHC-psi, pcDNA-Luc-psi seemed to produce more
stable mRNA transcripts (Figure 2B). At day 4, luciferase
mRNA levels increased in all transfected cells, due to
actinomycin D inactivation or clearance.
Using the same protocol, we measured the amount of
truncated mRNA in cells transfected with pCMV-5
LTR-psi-Luc or pCMV-5LTR-psi-Luc-UTR plasmids.
pCMV-5LTR-psi-Luc gave the lowest level of mRNA
expression as compared with pCMV-5LTR-psi-Luc-3
UTR Vimentin or pCMV-5LTR-psi-Luc-3UTR NMHC
(Figure 2C). Adding actinomycin D had no effect on the
expression profile of the 3 individual plasmids (Figure 2C).
For this retroviral platform, we could only observed a trend
suggesting that RNA from the pCMV-5LTR-psi-Luc- 3
UTR NMHC could be more stable than that from pCMV-5
LTR-psi-Luc or pCMV-5LTR-psi-Luc-3UTR Vimentin
(Figure 2D).
Evaluating modified mRNA expression
We next evaluated the functionality of the modified
mRNAs in transfected cells. At 1 to 4 days after
transfection, luciferase expression was increased with
pcDNA-Luc-UTR-psi plasmids containing vimentin
UTR and also with NMHC UTR, but not significantly
(Figure 3). To investigate any correlation of mRNA stability
with a long-term expression of the transgene, we mea-
sured luciferase activity following actinomycin D treatment
(Figure 3A). The background, putatively resulting from the
accumulation of the marker protein, was considered
negligible because we evaluated luciferase expression 1 day
after actinomycin D exposure. This lag time signifi-
cantly exceeded the time needed for the clearance of
the luciferase expressed at the early time point, this
protein having a 2-h half-life [30]. Again, luciferase
expression was significantly increased in cells transfected
with pcDNA-Luc-UTR-psi containing the vimentin UTR.
Therefore, we concluded that UTR regions from vimentin
improved mRNA expression, possibly through increased
mRNA stability or translation.
Luciferase expression obtained with truncated retro-
viral mRNA, was comparable to or lower when com-
paring cells transfected with pCMV-5LTR-psi-Luc to
Figure 1 Schematic representation of luciferase vectors used for recruitment into retroviral particles. psi: MLV packaging signal. PBS:
retroviral primer binding site. PPT: polypurine tract, priming + strand synthesis following the fist jump during reverse transcription. pA: Bovine
Growth Hormone polyadenylation signal. The last two constructs (pMNGag-Pol and pCMV-Env-Ampho) were used for transcomplementation in
order to drive particles formations.
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pCMV-5LTR-psi-Luc-3UTR Vimentin or pCMV-5
LTR-psi-Luc-3UTR NMHC (Figure 3B). Actinomycin D
did not change the profile or the ratio of the expression
for each construct (Figure 3B). While the RNA levels mea-
sured seemed to be the highest (Figure 2D), pCMV-5
LTR-psi-Luc-3UTR NMHC gave the lowest Luciferase
expression (Figure 3B). This could be explained by the
activity of Let-7f, a miRNA targeting NMHC 3UTR and
expressed in various cell types [31].
Recruiting mRNA into retroviral particles
To evaluate the recruitment of simple and truncated
mRNA into retroviral particles, each vector was transfected
with MLV packaging constructs. For each condition, a
same minimal amount of a GFP expression vector
was co-transfected. We harvested culture supernatants
for the different vectors at 48 and 72 h after transfection,
and analysed luciferase-mRNA content of retroviral
particles by RT-qPCR. At 48 h post-transfection, we exam-
ined recruitment of simple and truncated mRNA into
retroviral particles by RT-qPCR (Figure 4). All results were
normalised according to transfection efficiencies based on
GFP expression determined by FACS analysis at the time of
supernatant harvest. We obtained only a faint level of pack-
aging for pcDNA-Luc, the control expression vector for
Luciferase lacking a retroviral psi, which confirmed the
crucial role of a retroviral packaging signal for mobilizing
mRNA into retroviral particles. As another control,
RT-qPCR confirmed that the unique expression of a
retroviral envelope was not associated with luciferase-
mRNA packaging (Figure 4, lane 3). For psi containing
mRNAs, the RT-qPCR indicated packaging of all mRNA
products (Figure 4, lanes 610). While not statistically sig-
nificant, we also noticed a clear trend, suggesting that
Figure 2 mRNA cellular persistence: quantitative RT-PCR of Non-viral (A and B) and Truncated-retroviral (C and D) mRNA. 293FT cells
were transfected with constructs. One day after transfection, transcription was blocked by actinomycin D, and luciferase-mRNA levels were
measured at 24, 48 and 72 h. Luciferase mRNA was normalized to that of actin. (A and C) Comparison of luciferase mRNA level in transfected
cells, for each condition the amount was normalized to that of b-actin in cells transfected with pcDNA-Luc-psi or pCMV-5LTR-psi-Luc and
pcDNA-Luc-psi-UTR or pCMV-5LTR-psi-Luc-UTR. The bars indicate relative amounts compared to control condition (in A pcDNA-Luc-psi and in
C pCMV-5LTR-psi-Luc). Number of experiments, N = 2. (B and D) Evolution of the specific amount of the different RNAs. RNA extracted from cells
immediately after the addition of actinomycin D (time-point 0) was used to define the initial level of mRNA and arbitrarily set to 100%, at 24, 48
and 72 hours the amount of the different RNAs are compared to this initial point. Number of experiments, N = 2.
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truncated-retroviral vector-RNAs were more potent in
promoting mRNA packaging (Figure 4, lanes 6,8,10), as
compared with simple mRNAs (Figure 4, lanes 5,7,9).
Also, within pcDNA-Luc-UTR-psi or pCMV-5LTR-psi-
Luc-UTR, results did not significantly differ from each
other (Figure 4).
Transfer study of simple and truncated mRNA into cells
To assess the retroviral transferability of the modified
mRNA, we used the supernatant generated using cells
co-transfected with test-vectors and MLV packaging
constructs. 293FT target cells were then transduced with
equivalent amount of retroviral particles harvested 48
and 72 h post-transfection. We evaluated the transfer of
packaged mRNA into transduced cells by RT-qPCR as
above and by measuring luciferase activity 3 and 6 h
after transduction (Figures 5 and 6).
For RT-qPCR analysis of RNA delivery, all results were
normalised as described above. To circumvent stability
interference, the RNA transfer was studied shortly after
transduction. RT-qPCR analysis revealed luciferase-
mRNA in cells transduced for almost all conditions. As
previously shown for mRNA recruitment, we observed a
tendency indicating that the level of luciferase mRNA
was slightly higher in cells transduced with retroviral
particles containing truncated retroviral mRNA (pCMV-
5LTR-psi-Luc-UTR) (Figure 5, lanes 6,8,10). Moreover,
the level of luciferase mRNA was increased in cells
transduced with retroviral particles containing mRNA
with the NMHC UTR (Figure 5; lanes 9 and 10). Finally,
the luciferase mRNA level was only slightly decreased at
6 h post transduction (Figure 5; compare black and grey
bars), which suggests that the retrovirally transferred
mRNA harboured a certain stability following cell entry.
Of note, RT-qPCR analysis revealed luciferase mRNA
even in cells transduced with retroviral particles from
cells producing a retroviral vector missing an envelope
(Figure 5, lane 2). Thus, part of the signal observed
in RNA-test conditions corresponded to retroviral parti-
cles adsorbed at the surface of transduced cells. Im-
portantly, the signal obtained with the supernatant from
particles produced without psi-containing luciferase-
mRNA was almost not detectable, which confirmed the
negligible contribution of non-specific packaging (Figure 5,
lane 4).
We next evaluated the functionality of transduced
mRNAs by a luciferase assay. 293FT cells were transduced
with retroviral particles for 3 or 6 h, and then cells were
lysed to allow measurement of luciferase-activity (Figure 6).
Importantly, in contrast to RT-qPCR results, retroviral
particles without any functional (fusogenic) envelope did
not promote luciferase expression (Figures 5 and 6;
compare lanes 2). This indicated that the simple adsorption
of the particles was not sufficient to direct mRNA delivery.
Figure 3 Luciferase expression from Non-viral (A) and
Truncated-retroviral (B) constructs. 293FT cells were transfected
with the different constructs. One day after transfection, transcription
was blocked by actinomycin D. 2 to 4 days post-transfection,
luciferase activity was measured in lysed cells. Number of
experiments, N = 3. (3A) The analysis was performed using
pcDNALuc-psi as comparator for each condition. To evaluate the
significance of the observed differences, we performed a one
sample t-test. This statistical test allowed us to determine if the
means observed for pcDNA-Luc-Vimentin-psi and pcDNA-
Luc-NMHC-psi were significantly different to the reference value
fixed to 1, which correspond to pcDNA-Luc-psi. *p-value <0.05. (3B)
As the signal from pCMV-5LTR-psi-Luc was not different from the
one from pCMV-5LTR-psi-Luc-Vimentin, we evaluated the
significance of the observed differences between pCMV-5LTR-psi-
Luc-Vimentin and pCMV-5LTR-psi-Luc-NMHC, this was achieved with
a Wilcoxon-MannWhitney. *p-value < 0.05.
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Interestingly, we observed that luciferase expression was
higher in cells transduced with retroviral particles pack-
aging pcDNA-Luc-UTR-psi mRNAs (Figure 6, lanes 5,7,9)
than with pCMV-5LTR-psi-Luc-UTR, the truncated retro-
viral vector RNA (Figure 6, lanes 6,8,10). Among the
pcDNA-Luc-UTR-psi mRNAs, the highest expression
seemed to be for pcDNA-Luc-NMHC-psi (Figure 6, lane
9). Luciferase activity remained stable between 3 and 6 h
after transduction (Figure 6, compare black and grey bars),
which suggested a certain stability of the mRNAs, but the
2 hours half-life of the luciferase could also partially
explain this observation.
Together, these results demonstrated that mRNAs
packaged into retroviral particles were productively
transferred into cells since they were translated into
functional proteins. Despite the short half-life of lucifer-
ase, we still could observe a weak but detectable activity
of supernatants collected from cells expressing lucifer-
ase, even after 9 h at room temperature (data not
shown). Hence, we wanted to ensure that the luciferase
Figure 4 Recruitment of the modified mRNA into retroviral particles. Quantitative RT-PCR analysis of luciferase-mRNA content extracted
from retroviral particles produced in cells transfected with the packaging constructs and the test-constructs, 48 h post-transfection. All results
were normalized for transfection-efficiency with GFP expression determined by FACS analysis. Comparisons were performed using Wilcoxon-
MannWhitney analysis. NT: untransfected cells. Number of experiments, N = 3.
Figure 5 Retroviral transfer of mRNA into 293FT cells using relative RT-qPCR analysis. Quantitative RT-PCR analysis of luciferase mRNA
levels in 293FT cells, 3 and 6 h post-transduction with retroviral particles harvested 48 h post-transfection, in each condition the luciferase mRNA
was normalized to that of β-actin. Comparisons were performed using Wilcoxon-MannWhitney analysis, despite a tendency, no statistically
significant differences could be observed. NT: untransfected cells. Number of experiments, N = 3.
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activity detected in transduced cell lysates was due to
mRNA transfer and their translation and not to passive
luciferase transfer or pseudotransduction [32]. Therefore,
we pre-treated 293FT cells with 3 μg/ml of the translation
inhibitor puromycin, 1 h before transduction (Figure 7).
Negative control vectors showed no activity (Figure 7,
lanes 2 to 4). Cells treated with puromycin showed a sig-
nificantly lower luciferase activity after retroviral mRNA
transduction (Figure 7, lanes 5 to 10, black vs grey bars).
The persistence of some signal upon treatment however
indicated some escape from puromycin inhibition or some
passive transfer of the Luciferase. We failed to elucidate
the contribution of these two possibilities, since higher
concentrations of puromycin were deleterious, leading to
strong and rapid cell death (Data not shown). Neverthe-
less, these observations confirmed that the luciferase ac-
tivity measured in transduced cells truly resulted from the
translation of the retrovirally transferred mRNA.
Figure 6 Luciferase activity upon retroviral transfer of mRNA into 293FT cells. 293FT cells were transduced with 100 μl supernatants
containing retroviral particles harvested 48 h post-transfection. 3 or 6 h post-transduction, cells were lysed and luciferase activity was
measured. We observed a statistically significant difference between the control condition 4 and all the test constructs (5 to 10) (p-value < 0,03).
Statistical comparisons between the different constructs were performed on the 3 hours time-point and evaluated using a Wilcoxon-Mann
Whitney analysis. hptr, hours post-transfection. NT: untransfected cells. Number of experiments, N = 3.
Figure 7 Luciferase activity upon retroviral transfer of mRNA into 293FT cells with and without translation inhibitor. 293FT cells were
transduced with 100 μl supernatants containing retroviral-particles with or without 3 μg/ml puromycin. After 3 h, cells were lysed and luciferase
activity was measured. Results were normalized by transfection efficiency with GFP expression by FACS analysis. The significance of the
differences observed between the two conditions was determined by a Wilcoxon-MannWhitney analysis. NS : Not Significant. NT: untransfected
cells. Number of experiments, N = 3.
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Discussion
Replication deficient retroviral vectors have been widely
used in gene therapy because they promote high and
long-lasting transduction efficiency [33,34]. However,
because of insertional mutagenesis resulting from genomic
integration, standard retroviral gene transfer should not be
the preferred strategy for inducing differentiation to cure
non-lethal chronic diseases in humans [35]. In recent years,
various studies have shown that transfer of mRNA could
fulfill the safety goals required for treating human diseases
[1,2,36-38]. Besides the prominent advantage of a lack of
integration, mRNA-based gene transfer may also prevent
long-lasting expression of genes with pleiotropic effects
and potential for cancer promotion.
Following its translocation into the cytoplasm, mRNA
appears to be fairly unstable, which was considered a
major hurdle to convert these molecules into therapeutic
agents. Factors controlling mRNA degradation can be
cis-acting or trans-acting [39]. Among the features influ-
encing mRNA half-life, the polyA tail plays an important
role in both mRNA translation and stability. The polyA
tail inhibits decapping as well as degradation of mRNA
[40]. Particularly in retroviruses, including murine
gammaretroviruses, the efficiency of polyadenylation can
be poor [41]. While it is more a concern for the safety of
integrated retroviral vectors, polyadenylation might also
influence the encapsidation of genomic RNA, by redu-
cing the amount of stable transcripts during production.
Interestingly, this characteristic is amenable to modifica-
tion [6]. In addition, the UTR sequences of eukaryotic
mRNAs have been implicated in mRNA processing,
polyadenylation, stability, sub-cellular localization and
translational regulation [3,17]. The 3 UTR sequences
contain signals involved in mRNA decay, one of the
most-studied signals being AU-rich elements (AREs).
Such sequences were described to control or promote
rapid deadenylation-dependant mRNA decay [4,42].
mRNAs that contain AREs are unstable and their half-life
is increased when AREs are replaced with the 3 UTR of
mRNAs showing a stable profile [43].
Considering the above data, we thought that improv-
ing mRNA stability could influence recruitment into
retroviral particles. We designed a series of constructs
harbouring the UTRs from genes encoding abundant
cellular proteins flanking the luciferase gene. To enable
the retroviral recruitment we inserted an MLV packaging
signal [8,11]. We choose a minimal packaging sequence to
reduce the size of the transferred mRNA as much as
possible and because it was shown to be as efficient as a
full length sequence [44]. However, our data suggest that
the packaging step of mRNA remained susceptible to
improvement, since truncated retroviral RNAs appeared
to be more efficiently packaged than psi-containing
mRNA (Figure 4). Among the features that could improve
retroviral mRNA transfer, we thought that UTR-donating
molecules from abundantly expressed proteins could be
critical. However, the choice of such sequence was not
trivial since, despite a high level of expression within cells,
the UTRs from β-globin or β-actin did not increase
mRNA stability or improve luciferase expression (data not
shown). We hence focused our studies on the vimentin
and NMHC UTRs. Examination of the steady-state level
of the constructs at different times after blocking transcrip-
tion by actinomycin D suggested that larger amounts of
mRNA were detectable upon transfecting constructs
containing the 5 and 3 UTRs from vimentin (Figure 2).
However, actinomycin D strongly decreased the amount of
all tested mRNA, which suggested that changing the UTR
in the initial vector, for UTRs from vimentin and NMHC,
did not change mRNA stability (Figure 2 C and D).
Interestingly, we found that stability was not the unique
characteristic to look for, because the most efficient RNAs
for expression in cells were not necessarily those harbouring
the most stable profile (Figure 2 and 3; for the vimentin
UTRs). Importantly, in transduced cells, expression appears
to result from a combination of efficient packaging and
translation (Figure 4 and 6). Following transduction, it is
conceivable that the stability observed for vimentin-UTR
-containing mRNA could nevertheless influence expression
(Figure 3A). Altogether, these data suggest that the choice
of UTR sequence remains essentially empirical and
that all steps, from production to transduction, should
be experimentally tested. However, recent high-throughput
computational analysis of whole-genome data could guide
future selection processes [42].
We also generated constructs based on RNAs from a
regular retroviral vector (pBullet-Luc) truncated at the
3 end. To avoid genomic integration of the vectors, we
replaced the 3 LTR of pBullet-Luc with UTRs from
vimentin or NMHC (Figure 1). The 3 UTR from NMHC
allowed the highest level of expression and packaging
(Figure 5). The NMHC 3 UTR sequence contains a cyto-
plasmic polyadenylation element (CPE) (+1280 to 1370;
http://utrdb.ba.itb.cnr.it), with the general structure
UUUUUUAU [45] which could explain the stability of the
mRNA. However, although the NMHC 3 UTR sequence
appeared the most transcriptionally potent, during
production, expression of the transgene was better with
control vector or vectors with the vimentin 3 UTR
(Figure 3). This latter UTR contains a cis-acting element
(+61 to +115) [46] able to fold into a Y-shaped secondary
structure and important for vimentin mRNA function and
localization in the perinuclear region of the cytoplasm. As
for psi-containing mRNA, adding this 3 UTR to mRNA
led to almost equal recruitment of the mRNA into retro-
viral particles and equivalent luciferase expression in
target cells (Figure 4 and 6). In the present study we have
not addressed the question of a possible influence of a
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miRNA expressed in 293FT cells on the studied mRNAs.
Let-7f was recently described to target NMHC [31], also
the mirDB (mirDB.org) identified 25 possible miRNA for
the NMHC and 17 for the vimentin, among which
miR138 for example [47]. For future design of vectors, an
adaptation of the UTR to the miRNA expressed within
the target cell should take this into account.
Importantly, comparing truncated retroviral vectors to
psi-containing mRNAs showed that, although the
amount of mRNA transferred looked increased in the
former (Figure 4), they promoted lower luciferase
expression in transduced cells (compare each condition
in Figures 4 and 6). Since they were different in their 5
UTR, we acknowledge that expression of the reporter
gene could be influenced by other factors than mRNA
stability. It is noteworthy that the truncated mRNA still
contained the primer binding site, allowing for the for-
mation of the strong stop during reverse transcription
[48]. During strong stop formation, the RNaseH activity
hydrolyses the template RNA. Thus, the 3 truncation
within the retroviral genome could generate an uncapped
genomic RNA, which can be possibly less effective for
translation. This was not expected since we thought that
the presence of an internal ribosomal entry site en-
compassing the retroviral packaging signal could promote
translation of those cap-deficient mRNAs [13,16]. In the
pioneer study by Galla et al., efficient transfer was obtained
by ablating the primer binding site, which blocked the
formation of the strong stop, the first molecular species
synthesized during reverse transcription [14,48]. Accord-
ingly, translation of truncated mRNAs will certainly take
advantage of the deletion of the primer-binding site. A
highly context-dependent translation of the retroviral
genome was recently described [49], suggesting that further
studies addressing the retroviral UTR sequence could help
in defining the most efficient context for mRNA translation
upon transfer. Looking for further improvement, it is
noteworthy that the stability of synthetic mRNA could be
improved by a combination of nucleoside optimisation and
the choice of the UTR content [50].
Conclusions
In summary, using a retroviral mobilization system, we
have been able to efficiently recruit various mRNAs into
retroviral particles. Furthermore, viral transfer of such
mRNAs into target cells led to a transgene-induced bio-
logical effect, which validates the development of this
approach for future use in cell re-programming. At
present, the system appears more suitable for specific,
transient, low-level expression of a transgene. In the
future, retroviral RNA-mobilisation vectors may be further
improved by thoroughly evaluating other combinations of
UTRs, use more stable cDNA coding sequences [50] and
the addition of constitutive transport elements, which
increase the amount of cytoplasmic packageable RNA
[51]. All these adaptations should increase the mRNA
level in the producing cell and thereby extend the
applications of retroviral mRNA transfer.
Methods
Plasmid construction
PCR and specific primers were used to obtain the entire
luciferase Firefly sequence (Table 1) which was cloned
into the pcDNA3.1(−) vector (Invitrogen) at the HindIII
and KpnI sites to generate pcDNA-Luciferase. PCR was
used with specific primers to obtain the 5 and 3 UTRs
from human vimentin and non-muscular myosin heavy
chain (NMHC, MYH9) (beginning 3 of the stop codon
and extending to the first polyA site) (Table 1), which
were subcloned into the pGemTeasy vector (Promega).
To generate pcDNA-Luciferase-5UTR plasmids, the 5
UTR sequence was cloned into the NheI-HindIII site in
the pcDNA-Luciferase vector, and to generate pcDNA-
Luciferase-3UTR plasmids, the 3 UTR sequence was
cloned into the KpnI-NotI site in the pcDNA luciferase
vector.
To generate pcDNA-Luciferase-psi-UTR, psi derived
from the MLV virus (+206; +512) was amplified from
pLNCX with use of specific primers (Table 1) and
cloned into the KpnI site 3 of the luciferase gene in
pcDNA-Luc and pcDNA-Luc-UTR plasmids (Figure 1).
To generate truncated mRNA, the pBullet-Luc plasmid
was digested with SacI and ClaI or SacI and EcoRV. The
fragment containing the 5 LTR, psi and the luciferase
gene was cloned into pcDNA-Luc and pcDNA-Luc-UTR.
The resulting plasmids containing optimal packaging
sequences were designated pCMV-5LTR-psi-Luc and
pCMV-5LTR-psi-Luc-3UTR (Figure 1).
Cells
The 293FT cells (derived from the clone ATCC CRL-11268)
were maintained in Dulbeccos modified Eagles medium
(DMEM) (GlutaMAX) supplemented with pyruvate,
penicillin (100 U/ml), streptomycin (100 μg/ml), 10%
heat inactivated fetal calf serum and 1% non-essential
amino acids.
Assessment of mRNA stability
293FT cells were seeded at 200,000 cells per well into
24-well plates and grown overnight at 37°C, then
transfected with 200 ng of each construct using the Fugene
6 transfection reagent (Roche). After 10 h, cells were
washed with phosphate buffered saline (PBS), and fresh
medium was added. After 24 h, actinomycin D (1 μg/ml,
Sigma-Aldrich) was added into each well. At 2 to 4 days
post-transfection, cells were washed 3 times with PBS and
harvested; total RNA was extracted by use of the
Nucleospin RNAII kit (Macherey Nagel). Cells were also
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harvested on the day of actinomycin D treatment. To
eliminate plasmid DNA contamination, RNA samples
were treated once with TURBO DNase (2 U/μl, Ambion)
and purified by use of the RNA clean-up kit (Macherey
Nagel). To confirm the absence of plasmid DNA contam-
ination, an end-point PCR was performed on each RNA
samples, negative results allowed us to proceed further
the experiment (not shown). First-strand cDNA synthesis
involved the Superscript First-Strand II Synthesis system
(Invitrogen) with 300 ng total RNA and random
hexamers. Quantitative PCR involved the Light Cycler-
480-II system (Roche). PCR amplification of the reaction
mixture (2 μl of reverse transcriptase product, 1X SYBR
Green I master mix [Roche], 10 μM each primer and
RNase-free water to a final volume of 20 μl) involved 5
min pre-amplification at 95°C, 45 cycles of 10 seconds at
60°C and 10 seconds at 72°C, then melting curve and
cooling steps. PCR amplification involved use of the pri-
mer sequences for luciferase, forward, 5-CAACTgCATA
AggCTATgAAgAgA-3 and reverse, 5-ATTTGTATTCA
gCCCATATCgTTT-3 (Makawa et al., 2008); and β-actin,
forward 5-CgCACCACTggCATTgTCAT-3 and reverse,
5-TTCTCCTgATgTCACgCAC-3), as a normalization
control. Data are expressed as the mean of 2 experiments
performed in duplicate.
293FT cells were seeded at 30,000 cells per well into
96-well plates and grown overnight at 37°C. Fugene 6
transfection reagent (Roche) was used to co-transfect
cells with 50 ng pCDNA-Luc-psi, pCDNA-Luc-psi-UTR,
pCMV-5LTR-psi-Luc or pCMV-5LTR-psi-Luc-UTR
and 5 ng pGL4.74 (Promega) containing Renilla lucifer-
ase to normalize Firefly luciferase. At 24 h post-
transfection, actinomycin D (1 μg/ml) was added to each
well. At 2 to 4 days post-transfection, Firefly luciferase
expression was measured by Dual-Glo luciferase assay
(Promega) with normalization to Renilla expression.
Activity for each construction was compared to that for
pcDNA-Luc-psi alone.
Cell transfection and retroviral particle production
293FT cells were plated at 4.2×106 cells per plate into a
10-cm dish and grown overnight. Fugene 6 transfection
reagent was used to transfect cells with 1 μg pMNGag-Pol,
1 μg of pCMV-Env encoding an amphotropic envelope, 80
ng of a reporter plasmid for normalization, pEGFPC1, and
3.22 10-13 mole of the different test constructs, pcDNA-
Luc-psi-UTR or pCMV-5LTR-psi-Luc-UTR or control
constructs lacking the retroviral psi, pcDNA-Luc. After 10
h, the medium was removed and cells were washed with
PBS, then fresh medium was added. After 48 and 72 h,
retroviral particles containing supernatants were harvested,
filtered through a 0.45-μm-pore filter (Millipore) and incu-
bated for 3 h at 4°C before 293FT transduction. pBullet-
Luc, pMNGagPol and pCMV-Ampho were used as positive
controls. pBullet-Luc, pMNGagPol or pBullet-Luc, pCMV-
Env without pMNGagPol were used as negative controls.
Quantitative real-time RT-PCR
To evaluate mRNA transfer, 293FT cells (230,000 cells/well
in 24-well plates) were transduced with 500 μl supernatants
containing retroviral particles. Transduction was improved
by the addition of polybrene (5 μg/ml) and centrifugation
for 1 h at 1900 rpm and 37°C. After 3 and 6 h, medium
was removed and cells were washed 3 times with PBS.
Then cells were harvested and total RNA was extracted by
use of the Nucleospin RNAII kit (Macherey Nagel). To
eliminate plasmid DNA contamination, total RNA was
treated with Turbo DNAse (2 U/μl; Ambion) and purified
using Nucleospin RNA clean-up kit (Macherey Nagel)
according to the manufacturers instructions. The efficiency
of this treatment was verified using end-point PCR, nega-
tive results allowed us to proceed further the experiment
Table 1 Primers for PCR amplification
Target Primer Primer Sequence (5-3) Sequence Length
Luciferase Luciferase-S 5-TCgAAgCTTACCATggAAgACgCCA -3 1677 bp
Luciferase-AS 5-gAATggTACCTTACAATTTggAC -3
Vimentin Vimentin-5UTR-AS 5 ATCggCTAgCgCgTCCCCgCgCCAg -3 144 bp
Vimentin-5UTR-AS 5-gAATAAgCTTggCTgCggAgggT -3
Vimentin-3UTR-S 5-ATCgggTACCAAATTgCACACAC -3 325 bp
Vimentin-3UTR-AS 5-gAATgCggCCgCgAAgCAgAACC -3
Myosin Myosin-5UTR-S 5-TCggCTAgCgAAggCTAAgCA -3 154 bp
Myosin-5UTR-AS 5-AATTAAgCTTACCTgAACCTg -3
Myosin-3UTR-S 5-ATCgggTACCgCCTCTTCTCCTg -3 1389 bp
Myosin-3UTR-AS 5-gAATgCggCCgCgTgATgCTCAg -3
MLV Packaging signal psi-S 5 = AAAgTggTACCgggAggTAAgCT-3 322 bp
psi-AS 5-gCCTTggTACCgAACTgTTTTAg-3
Sequence amplified for modifying the vectors (restriction sites used allowing the cloning are in bold).
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(Not shown). cDNA synthesis was performed as above. In
total, 2 μl cDNAs were used for quantitative RT-PCR
(RT-qPCR) with SYBR Green I Master and LightCycler-
480-II (Roche). RT-qPCR was carried out as above.
To assess mRNA mobilisation into retroviral particles,
RNA was extracted from 140 μl supernatants containing
retroviral particles by use of the QIAamp viral RNA
Mini-kit (Qiagen). After extraction, RNA was treated
with TURBO DNAse (2 U/μl; Ambion). Then, DNAse
was removed using the Nucleospin RNA clean-up kit
(Macherey-Nagel) according to the manufacturers
instructions. An end-point PCR was performed to verify
that there was no plasmid DNA contamination in the
RNA treated with DNAse (Not shown). In total, 4 μl
RNA treated with TURBO DNAse (2 U/μl) was used
for cDNA synthesis with the Superscript First-strand
Synthesis System (Invitrogen). Luciferase RNA copies
were quantified by qRT-PCR with luciferase primers and
the SYBR Green I master Kit (Roche) as above. The RNA
copy number was calculated by an external standard curve
of serial dilution of pBullet-Luc plasmid.
Luciferase assay
On the day before transduction, 60,000 cells were seeded
in 96-well plates. On the day of transduction, 100 μl
supernatants containing retroviral particles were applied to
cells with or without 3 μg/ml puromycin. This translation
inhibitor was added 1 h before transduction. Transduction
was assisted by the addition of polybrene (5 μg/ml) and
centrifugation for 1 h at 1900 rpm and 37°C. At 3 and 6 h
post-transduction, luciferase expression was determined by
use of the Bright-Glo luciferase assay (Promega) and a
Centro LB 960 luminometer (Berthold Technologies). Each
assay was performed in triplicate; all experiments were
repeated 3 times.
Statistical analysis
Statistical analyses were performed on 3 independent exper-
iments. Each experiment was carried out in triplicate. Data
are expressed as mean ± SD; WilcoxonMannWhitney,
one sample t-test or one sample t-test were used to analyse
the data.
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